Nanoviricides, Inc. (NNVC): R&D Expense
$5.55M
Year ended 2025-06-30
$4.58M
Trailing 12 months to 2026-03-31
-1.4%
3-year compound annual growth
+3.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $5.55M | +2.1% | 2025-09-29, From 2024-07-01 |
| 2024-06-30 | $5.44M | -14.9% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $6.39M | +10.5% | 2024-09-27, From 2022-07-01 |
| 2022-06-30 | $5.78M | -5.4% | 2023-10-13, From 2021-07-01 |
| 2021-06-30 | $6.11M | +30.2% | 2022-10-13, From 2020-07-01 |
| 2020-06-30 | $4.70M | -20.7% | 2021-10-12, From 2019-07-01 |
| 2019-06-30 | $5.92M | +0.1% | 2021-10-12, From 2018-07-01 |
| 2018-06-30 | $5.91M | -9.9% | 2020-10-13, From 2017-07-01 |
| 2017-06-30 | $6.57M | n/c | 2019-08-23, From 2016-07-01 |
| 2016-06-30 | $5.03M | +37.4% | 2018-10-12, From 2015-07-01 |
| 2015-06-30 | $3.66M | -28.7% | 2017-09-28, From 2014-07-01 |
| 2014-06-30 | $5.13M | +19.5% | 2016-09-16, From 2013-07-01 |
| 2013-06-30 | $4.29M | +0.6% | 2015-09-14, From 2012-07-01 |
| 2012-06-30 | $4.27M | +2.6% | 2015-02-23, From 2011-07-01 |
| 2011-06-30 | $4.16M | n/a | 2013-10-08, From 2010-06-30 |
| 2010-06-30 | $3.37M | n/a | 2012-10-26, From 2009-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $5.55M | +2.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare NNVC, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗